Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
K. Rachael Parks,
Anna J. MacCamy,
Josephine Trichka,
Matthew Gray,
Connor Weidle,
Andrew J. Borst,
Arineh Khechaduri,
Brittany Takushi,
Parul Agrawal,
Javier Guenaga,
Richard T. Wyatt,
Rhea Coler,
Michael Seaman,
Celia LaBranche,
David C. Montefiori,
David Veesler,
Marie Pancera,
Andrew McGuire,
Leonidas Stamatatos
Affiliations
K. Rachael Parks
Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA
Anna J. MacCamy
Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Josephine Trichka
Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Matthew Gray
Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Connor Weidle
Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Andrew J. Borst
Department of Biochemistry, University of Washington, Seattle, WA, USA
Arineh Khechaduri
Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Brittany Takushi
Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Parul Agrawal
Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Javier Guenaga
IAVI Neutralizing Antibody Center, Department of Immunology and Microbiology, The Scripps Research Institute, San Diego, CA, USA
Richard T. Wyatt
IAVI Neutralizing Antibody Center, Department of Immunology and Microbiology, The Scripps Research Institute, San Diego, CA, USA
Rhea Coler
Department of Global Health, University of Washington, Seattle, WA, USA; Infectious Disease Research Institute, Seattle, WA, USA
Michael Seaman
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Celia LaBranche
Laboratory for AIDS Vaccine Research and Development, Duke University, Durham, NC, USA
David C. Montefiori
Laboratory for AIDS Vaccine Research and Development, Duke University, Durham, NC, USA
David Veesler
Department of Biochemistry, University of Washington, Seattle, WA, USA
Marie Pancera
Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA; Corresponding author
Andrew McGuire
Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA; Corresponding author
Leonidas Stamatatos
Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA; Corresponding author
Summary: Broadly HIV-1 neutralizing VRC01 class antibodies target the CD4-binding site of Env. They are derived from VH1-2∗02 antibody heavy chains paired with rare light chains expressing 5-amino acid-long CDRL3s. They have been isolated from infected subjects but have not yet been elicited by immunization. Env-derived immunogens capable of binding the germline forms of VRC01 B cell receptors on naive B cells have been designed and evaluated in knockin mice. However, the elicited antibodies cannot bypass glycans present on the conserved position N276 of Env, which restricts access to the CD4-binding site. Efforts to guide the appropriate maturation of these antibodies by sequential immunization have not yet been successful. Here, we report on a two-step immunization scheme that leads to the maturation of VRC01-like antibodies capable of accommodating the N276 glycan and displaying autologous tier 2 neutralizing activities. Our results are relevant to clinical trials aiming to elicit VRC01 antibodies. : The conserved N276 glycan on the HIV-1 Env presents a major steric hindrance in the maturation of VRC01-class bnAbs. Here, Parks et al. discuss a two-step immunization scheme that leads to the development of VRC01-like antibodies that accommodate the N276 glycan on heterologous Env-derived proteins yet display limited neutralizing activities. Keywords: VRC01, broadly neutralizing antibodies, HIV-1, germline targeting, germline antibody, 426c Env, antibody maturation, CDRL1, CDRL3